These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 16484271

  • 1. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A.
    BMJ; 2006 Feb 18; 332(7538):416-9. PubMed ID: 16484271
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab: bound to rebound?
    Schiess N, Calabresi PA.
    Neurology; 2009 Feb 03; 72(5):392-3. PubMed ID: 19188569
    [No Abstract] [Full Text] [Related]

  • 3. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 03; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 4. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S, Berger JR.
    J Neurol Sci; 2008 Jan 15; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 15; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Aug 15; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 7. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 15; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab: bench to bedside and beyond.
    Rudick R, Polman C, Clifford D, Miller D, Steinman L.
    JAMA Neurol; 2013 Feb 15; 70(2):172-82. PubMed ID: 23128399
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar 15; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 10. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 11. The return of natalizumab: weighing benefit against risk.
    Goodin D.
    Lancet Neurol; 2006 May 14; 5(5):375-7. PubMed ID: 16632301
    [No Abstract] [Full Text] [Related]

  • 12. PML risk and natalizumab: more questions than answers.
    Ransohoff RM.
    Lancet Neurol; 2010 Mar 14; 9(3):231-3. PubMed ID: 20117056
    [No Abstract] [Full Text] [Related]

  • 13. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb 14; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 14. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
    Achiron A, Miron S, Shoenfeld Y.
    Isr Med Assoc J; 2005 May 14; 7(5):283-5. PubMed ID: 15909458
    [No Abstract] [Full Text] [Related]

  • 15. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.
    Neurology; 2011 Feb 08; 76(6):574-6. PubMed ID: 21300973
    [No Abstract] [Full Text] [Related]

  • 16. Multiple sclerosis woes.
    Nat Neurosci; 2005 Jul 08; 8(7):837. PubMed ID: 16136665
    [No Abstract] [Full Text] [Related]

  • 17. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2005 Jul 08; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 18. [Natalizumab in multiple sclerosis].
    Rajda C, Bencsik K, Vécsei L, Magyarországi Sclerosis Multiplex Centrumok Orvosi Tanácsadó Testület tagjai.
    Ideggyogy Sz; 2008 May 30; 61(5-6):204-8. PubMed ID: 18567397
    [No Abstract] [Full Text] [Related]

  • 19. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C.
    N Engl J Med; 2009 Sep 10; 361(11):1081-7. PubMed ID: 19741229
    [Abstract] [Full Text] [Related]

  • 20. The trials and tribulations of Tysabri.
    Lancet Neurol; 2006 May 10; 5(5):373. PubMed ID: 16632299
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.